Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most core drug-label mechanism/indication statements for ROCKLATAN are supported by the provided label excerpts (Sections 1 and 12.1), but several claims about specific pharmacologic actions (e.g., trabecular meshwork/Schlemm’s canal; Rho-kinase pathway inhibition), general class mechanism, and manufacturer/patent information are not supported by the supplied excerpts and cannot be verified against them.
Category Scores
Accurate Statements
Rocklatan is a prescription medication used to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Indications and Usage: “indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.”
Rocklatan is a dual-action medication.
Clinical Pharmacology 12.1: “ROCKLATAN is comprised of two components: netarsudil and latanoprost. Each of these two components decreases elevated IOP.”
Rocklatan contains netarsudil.
Drug description/Clinical Pharmacology 12.1: “ROCKLATAN is comprised of two components: netarsudil and latanoprost.”
Netarsudil improves the outflow of aqueous humor from the eye.
Clinical Pharmacology 12.1: “ROCKLATAN is believed to reduce IOP by increasing the outflow of aqueous humor.” (ROCKLATAN includes netarsudil and latanoprost.)
Rocklatan contains latanoprost.
Drug description/Clinical Pharmacology 12.1: “ROCKLATAN is comprised of two components: netarsudil and latanoprost.”
Latanoprost is a prostaglandin analog.
Indications and Usage: “a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue” (latanoprost is identified as the prostaglandin component in the label excerpts via the combination including latanoprost).
The combined mechanism of Rocklatan provides a dual pathway for IOP reduction.
Clinical Pharmacology 12.1: “two components… Each of these two components decreases elevated IOP.”
Unsupported Statements
Rocklatan belongs to the drug class known as prostaglandin analogs.
Provided label excerpt states ROCKLATAN is “a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue,” but does not label the overall drug as “a prostaglandin analog” as a class designation for the combination.
Netarsudil inhibits the Rho-kinase pathway.
The provided label excerpts call it “a Rho kinase inhibitor” but do not explicitly state “inhibits the Rho-kinase pathway.”
Netarsudil works by relaxing the trabecular meshwork and Schlemm's canal.
No provided label excerpt mentions trabecular meshwork or Schlemm’s canal.
Latanoprost increases the uveoscleral outflow of aqueous humor.
The provided label excerpts state ROCKLATAN is believed to increase the outflow of aqueous humor, but do not specify the uveoscleral pathway for latanoprost.
Other medications in the prostaglandin analog class include latanoprost, bimatoprost, travoprost, and tafluprost.
No provided label excerpt lists other prostaglandin analog drugs.
Prostaglandin analogs primarily work by increasing the outflow of fluid from the eye through the uveoscleral pathway.
No provided label excerpt states “primarily” or specifies the uveoscleral pathway.
Information regarding Rocklatan's patent expiry is available on DrugPatentWatch.com.
Not present in the provided label excerpts.
Rocklatan is manufactured by KalVista Pharmaceuticals.
Not present in the provided label excerpts.
Contradictions
Important Omissions
How to administer ROCKLATAN (one drop once daily in the affected eye(s) in the evening; do not exceed once daily; dosing separation guidance with other topical ophthalmics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Core indication and that ROCKLATAN reduces elevated IOP via increased aqueous humor outflow are supported. However, multiple mechanistic/classification statements (pathway-specific actions; prostaglandin class mechanism; other class examples) are unsupported by the supplied label excerpts. No explicit dosing or contraindication errors were asserted in the AI claims provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts (pathway-specific mechanistic details; uveoscleral outflow; prostaglandin class generalizations; patent/manufacturer statements).
Suggested Improvement
Limit statements to what is explicitly supported by the provided excerpts (fixed-dose combination of Rho kinase inhibitor + prostaglandin F2α analogue; two components each decrease IOP; believed increased aqueous humor outflow; labeled indication). Omit or qualify claims not present in the excerpts (trabecular meshwork/Schlemm’s canal; uveoscleral outflow specificity; other prostaglandin analog examples; patent/manufacturer sourcing).